Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The aim is to compare the blood pressure lowering effect of the combination of candesartan
cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32
mg alone, HCT 25 mg alone and placebo in hypertensive adults.